BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
View Top Employees from BioRestorative Therapies, Inc.Website | http://www.biorestorative.com |
Ticker | BRTX |
Revenue | $111000 |
Employees | 12 (8 on RocketReach) |
Founded | 1997 |
Address | 40 Marcus Drive Suite One, Melville, New York 11747, US |
Phone | (631) 760-8100 |
Fax | (631) 760-8414 |
Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
Industry | Business Services, Biotechnology Research, Health Care, Health Diagnostics, Therapeutics |
Web Rank | 16 Million |
Competitors | Athersys, Lorem Cytori USA, Inc, Minerva Biotechnologies, Regenestem, LLC, Regeneus Ltd |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular BioRestorative Therapies, Inc. employee's phone or email?
The BioRestorative Therapies, Inc. annual revenue was $111000 in 2024.
Yongxing Liu is the Director of Bioengineering of BioRestorative Therapies, Inc..
8 people are employed at BioRestorative Therapies, Inc..
BioRestorative Therapies, Inc. is based in Melville, New York.
The NAICS codes for BioRestorative Therapies, Inc. are [541714, 541, 5417, 54, 54171].
The SIC codes for BioRestorative Therapies, Inc. are [873, 87].